Coverage-gated living condition brief

Type 2 Diabetes peptide evidence brief

A cited Type 2 Diabetes peptide evidence brief across 39 exact-label ClinicalTrials.gov records, 15 connected profiles, and 7 registry-update years. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.

Registry records

39 selected records.

Connected peptides

15 profiles.

Registry update years

2014–2026 in selected records.

Direct collection answer · published August 17, 2026

What peptide evidence does PeptideScanner carry for Type 2 Diabetes?

PeptideScanner’s selected collection contains 39 retained ClinicalTrials.gov records carrying the exact condition label “Type 2 Diabetes,” connected to 15 peptide profiles across 7 registry-update years.

That answer describes this collection and the exact cited registry observations below. It is not a conclusion about whether any peptide treats Type 2 Diabetes, and it is not a safety or efficacy assessment.

Indication intelligence

Selected evidence landscape

Trial phases5

Phase labels copied from the retained ClinicalTrials.gov versions.

Registry statuses5

Overall statuses at each retained observation, not necessarily current today.

Across the connected peptide profiles, PeptideScanner also carries 407 selected PubMed records and 28 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Type 2 Diabetes unless their own cited source says so.

Related profile context

Literature connected through these peptide profiles

All literature facets →

This is a bounded sample of up to six PubMed bibliography records connected through peptide profiles on this hub, not the total profile literature count above. They are not condition-matched records, and their presence does not establish that they concern Type 2 Diabetes.

Orforglipron · source record 2026-11-09

Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight.

PubMed lists PMID 41994902 in Diabetes, obesity & metabolism as Clinical Trial, Phase I, Journal Article, Multicenter Study, Randomized Controlled Trial, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug orforglipron. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Liraglutide · source record 2026-10-18

Epicardial Versus Circulating Adiponectin: An Unresolved Distinction in Liraglutide's Anti-Arrhythmic Mechanism.

PubMed lists PMID 42891862 in Cardiovascular drugs and therapy as Letter, with publication-date metadata of 2026-10-17 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Dulaglutide · source record 2026-01-27

Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus.

PubMed lists PMID 29094890 in American family physician as Journal Article, with publication-date metadata of 2017-10-15 (day precision). PeptideScanner associated the retained record with the identity slug dulaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Open attributed literature record →

Collection change ledger

Recently changed records on this condition hub

All recent changes →

These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.

Record added

ClinicalTrials.gov record NCT02081118

PeptideScanner retained ClinicalTrials.gov record NCT02081118 at 2026-11-16T17:34:46.889Z. Its registry update date was 2016-08-09, and PeptideScanner's reviewed identity mapping was efpeglenatide.

PeptideScanner change date
November 16, 2026
Cited source date
August 9, 2016
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04208620

PeptideScanner retained ClinicalTrials.gov record NCT04208620 at 2026-11-16T01:47:38.899Z. Its registry update date was 2020-07-31, and PeptideScanner's reviewed identity mapping was cotadutide.

PeptideScanner change date
November 16, 2026
Cited source date
July 31, 2020
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05872620

PeptideScanner retained ClinicalTrials.gov record NCT05872620 at 2026-11-16T17:28:37.737Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was orforglipron.

PeptideScanner change date
November 16, 2026
Cited source date
September 4, 2026
Evidence lane
Clinical trials

Exact-record source chronology

Type 2 Diabetes registry timeline

All trial facets →

Years come from the last-update date on each retained ClinicalTrials.gov observation. They show source chronology, not when PeptideScanner added the record and not a continuous monitoring guarantee.

2026

31 records

2024

1 record

2023

2 records

2020

2 records

2016

1 record

2015

1 record

2014

1 record
What this brief cannot answer